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Abstract: Epithelial ovarian cancer (EOC) has a unique mode of metastasis, where cells shed
from the primary tumour, form aggregates called spheroids to evade anoikis, spread through the
peritoneal cavity, and adhere to secondary sites. We previously showed that the master kinase Liver
kinase B1 (LKB1) is required for EOC spheroid viability and metastasis. We have identified novel
(nua) kinase 1 (NUAK1) as a top candidate LKB1 substrate in EOC cells and spheroids using a
multiplex inhibitor beads-mass spectrometry approach. We confirmed that LKB1 maintains NUAK1
phosphorylation and promotes its stabilization. We next investigated NUAK1 function in EOC cells.
Ectopic NUAK1-overexpressing EOC cell lines had increased adhesion, whereas the reverse was seen
in OVCAR8-NUAK1KO cells. In fact, cells with NUAK1 loss generate spheroids with reduced integrity,
leading to increased cell death after long-term culture. Following transcriptome analysis, we identified
reduced enrichment for cell interaction gene expression pathways in OVCAR8-NUAK1KO spheroids.
In fact, the FN1 gene, encoding fibronectin, exhibited a 745-fold decreased expression in NUAK1KO
spheroids. Fibronectin expression was induced during native spheroid formation, yet this was
completely lost in NUAK1KO spheroids. Co-incubation with soluble fibronectin restored the compact
spheroid phenotype to OVCAR8-NUAK1KO cells. In a xenograft model of intraperitoneal metastasis,
NUAK1 loss extended survival and reduced fibronectin expression in tumours. Thus, we have
identified a new mechanism controlling EOC metastasis, through which LKB1-NUAK1 activity
promotes spheroid formation and secondary tumours via fibronectin production.
Keywords: ovarian cancer; spheroid; LKB1; NUAK1; metastasis; fibronectin
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1. Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy in the developed
world and it is characterized by early and rapid metastasis [1]. Most women are diagnosed with
advanced-stage disease with a five-year survival rate of only 29% [2]. The standard treatment plan
for patients with late-stage EOC is maximal surgical cytoreduction with adjuvant chemotherapy of
carboplatin and paclitaxel [1]. However, the majority of patients will eventually develop disease
recurrence and resistance to chemotherapy. Therefore, there is a need to develop novel therapeutic
strategies in order to impede EOC metastasis [3].
In EOC metastasis, malignant cells shed from the primary ovarian tumour and spread into
the peritoneal cavity [4]. Ascites commonly accumulates in the peritoneal cavity of patients with
advanced-stage disease. In the ascites fluid, cancer cells form multi-cellular structures that are known as
spheroids to evade anoikis, a form of apoptosis due to loss of cell attachment. Eventually, spheroids will
adhere to the peritoneum to continue to invade at secondary sites [5,6]. In addition to playing a key role
in efficient peritoneal metastasis, spheroids acquire resistance to chemotherapy due to the acquisition
of cellular quiescence [7,8].
The formation of spheroids is controlled by several cell attachments through cadherins and
indirectly through extracellular matrix (ECM) proteins and integrins [9–11]. Fibronectin exists as
a soluble form in the plasma and as an insoluble fibrillar form in the ECM [12]. Fibronectin is a
ligand for multiple integrins; however, its canonical receptor is the α5β1integrin heterodimer. In EOC,
the interaction between fibronectin and α5β1 integrins is necessary for efficient spheroid formation [11].
In fact, elevated fibronectin expression is correlated with a worsened tumour stage and decreased
overall survival in EOC patients [13]. In mouse models, fibronectin loss reduces EOC cell adhesion,
invasion, and metastatic potential [14].
The elucidation of key intracellular signaling pathways in ovarian cancer spheroids would allow
for an improved understanding of metastatic processes and would aid in the identification of novel
therapeutic targets. Our group previously showed that Liver kinase B1 (LKB1) is critical for ovarian
cancer metastasis [15,16]. LKB1, which is encoded by STK11, is a serine-threonine kinase that is known
best as having tumour suppressive-like activity in cancers [17]. STK11 inactivating mutations lead to
Peutz–Jeghers syndrome, a condition that is characterized by gastrointestinal polyps and increased risk
for cancer [18]. However, we have shown that LKB1 activity is intact and facilitates tumour progression
in late-stage EOC [15,16]. LKB1 is expressed in established EOC cell lines, patient-derived ascites
cells, and tumour extracts [16]. In addition, sustained LKB1 loss decreases the anchorage-independent
growth of EOC cells and decreases spheroid integrity and cell viability [15]. LKB1 loss extends survival
and decreases tumour burden in a xenograft model of intraperitoneal metastasis [15].
The canonical downstream target of LKB1 is AMP-activated protein kinase (AMPK), a regulator
of metabolic stress [17]. Interestingly, our group showed that LKB1’s pro-metastatic role in EOC occurs
independent of AMPK activity [15]. LKB1 is known as a master upstream kinase by its regulation of 12
other AMPK-related kinases (ARKs): brain-specific kinases 1 and 2 (BRSK1/2), novel (nua) kinases 1
and 1 (NUAK1/2), salt-inducible kinases 1, 2, and 3 (SIK1/2/3), microtubule-affinity regulating kinases
1, 2, 3, and 4 (MARK1/2/3/4), and SNF-related serine/threonine-protein kinase (SNRK) [19]. Herein,
we used a multiplex inhibitor bead-mass spectrometry analysis in order to identify NUAK1 as the
most likely ARK family member substrate enabling LKB1 to drive EOC metastasis.
NUAK1 is a serine-threonine kinase that can be phosphorylated by LKB1 at a conserved threonine
211 residue on the T-loop of its catalytic domain [19,20]. Prior studies have shown that NUAK1
has pro-tumorigenic functions. NUAK1 promotes cancer cell survival by inhibiting apoptosis and
inducing the S-phase in the cell cycle. It can also protect tumours from oxidative stress by increasing
nuclear translocation of the anti-oxidant regulator, Nrf2 [21]. Previous studies also suggest that
NUAK1 impacts cell adhesion by increasing epithelial–mesenchymal transition (EMT) and stimulating
cell detachment via myosin phosphatase complex regulation [22,23]. A tumour-promoting role for
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NUAK1 is strengthened by studies where elevated NUAK1 correlates with poor prognosis in several
malignancies, including EOC [21,24].
In this study, we aimed to further elucidate the role of the LKB1 target NUAK1 in EOC metastasis.
We show that LKB1 regulates NUAK1 expression, phosphorylation, and stability in EOC cells and
spheroids. NUAK1 controls key steps of the metastatic cascade by regulating EOC cell adhesion and
spheroid integrity via fibronectin expression and resultant deposition in order to promote spheroid
formation. Furthermore, NUAK1 loss in a xenograft model of intraperitoneal metastasis extended host
survival and reduced fibronectin expression in tumours.
2. Results
2.1. NUAK1 Expression is Regulated by LKB1 in EOC
We performed multiplex inhibitor beads-mass spectrometry (MIB/MS) to elucidate alternative
LKB1 substrates in EOC since we previously demonstrated that LKB1 is required for efficient EOC
metastasis, yet acts independently from its canonical target AMPK [15,16]. Briefly, several broad-acting
ATP-competitive kinase inhibitors are immobilized to beads to capture active kinases present in
protein lysates, which is then coupled with tandem mass spectrometry to identify and quantify eluted
kinases [25]. Our MIB/MS analysis was completed using OVCAR8 and OVCAR8-STK11KO cells that
were previously generated using CRISPR/Cas9 editing [15] (Figure 1A). Out of 12 ARKs, NUAK1 was
the only family member that was significantly decreased in STK11KO adherent cells and spheroids
(Figure 1B). In fact, it was the second most down-regulated kinase in spheroids (−8.75-fold change)
and third most-down-regulated kinase (−2.8-fold change) in adherent cells (Tables S2 and S3).
We assessed NUAK1 expression by immunoblot analysis and observed a significant decrease in
NUAK1 expression levels in OVCAR8-STK11KO spheroids to confirm our MIB/MS results (Figure 1C).
NUAK1 phosphorylation was examined to further study the regulation of NUAK1 by LKB1. NUAK1
is directly phosphorylated at Ser211 by LKB1 [17,20]; however, there are no commercially available
antibodies for this modification. Thus, we employed PhostagTM acrylamide gels [26] and observed
a significant decrease in phospho-NUAK1 due to LKB1 loss in OVCAR8 cells in both adherent and
spheroid culture conditions (Figure 1D). Thus, NUAK1 expression and phosphorylation require LKB1
in EOC cells and spheroids.
Finally, we sought whether LKB1 regulates NUAK1 expression in tumours. While using xenograft
tumour samples collected from our previous study [15], there was a significant decrease in NUAK1
protein expression in OVCAR8-STK11KO tumours as compared with OVCAR8 tumours (Figure 1E).
Altogether, our findings suggest that LKB1 regulates NUAK1 expression in ovarian cancer spheroids
and tumour samples.
2.2. NUAK1 Is Differentially Expressed during Spheroid Formation
Using a spheroid model of metastasis, we sought to determine whether NUAK1 expression
changes during spheroid formation. To achieve this, we commonly compare protein expression
between proliferative adherent cells and quiescent spheroids [7]. By examining spheroids generated
from high-grade serous ovarian cancer (HGSOC) cells lines OVCAR8 and OVCAR5 [27,28], we found
that NUAK1 protein levels are down-regulated in spheroids when compared to adherent cells
(Figure 2A). This trend was also apparent in multiple patient ascites-derived cell lines cultured as
spheroids, including cells from a Stage IIIB HGSOC patient who had received six cycles of carboplatin
and paclitaxel (iOvCa198) and upon platinum resistance (iOvCa247; Figure 2A). For comparison,
the non-HGSOC cell line HEYA8 [27] was examined. In contrast to HGSOC spheroids, HEYA8
spheroids showed increased NUAK1 as compared to adherent cells (Figure 2A).
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cells cultured as adherent cells (Adh) and spheroids (Sph) for 72 h. Tubulin was used as a loading
control. Densitometric analysis of phospho-NUAK1 expression relative to tubulin and normalized to
OVCAR8 cells and multiple t-test with Bonferroni correction was performed (** p < 0.01; **** p < 0.0001;
n = 3). Whole blot images can be found in Figures S5 and S6. (E) Immunoblot analysis of NUAK1
expression in OVCAR8 and OVCAR8-STK11KO xenograft tumours. Densitometric analysis of NUAK1
expression relative to tubulin for OVCAR8 tumours (n = 5) and OVCAR8-STK11KO tumours (n = 7).
Statistical analysis was performed using two-tailed Student’s t-test (* p < 0.05). Whole blot images can
be found in Figures S7 and S8.
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(B) Time course analysis of NUAK, phospho-LKB1 (S428), and total LKB1 during OVCAR8 spheroid
formation. Densitometric analysis for NUAK1 relative to tubulin, phospho-LKB1 relative to LKB1,
and LKB1 relative to tubulin. One-way ANOVA and Dunnett’s multiple comparison test were
performed (** p < 0.01; n = 3). Whole blot images can be found in Figures S19–S22. (C) RT-qPCR
analysis of NUAK1 gene expression in OVCAR8 and OVCAR8-STK11KO cells cultured under adherent
conditions (Adh) or as spheroids (Sph). Gene expression is relative to GADPH and normalized to
OVCAR8 adherent cells. Two-way ANOVA and Tukey’s multiple comparisons test was performed
(NS = non-significant; n = 3). (D) Immunoblot analysis of NUAK1 expression in OVCAR8 and
OVCAR8-STK11KO cells treated with 10 µM MG132 for 8 h, or 0.1% DMSO as a control. The cells were
cultured in adherent conditions (Adh) or as spheroids (Sph). Densitometric analysis of NUAK1 relative
to tubulin and normalized to DMSO-treated adherent cells. Two-way ANOVA and Tukey’s multiple
comparisons test were performed (NS = not significant; * p < 0.05; ** p < 0.01; **** p < 0.0001; n = 3).
Whole blot images can be found in Figures S23 and S24. (E) Immunoblot analysis of NUAK1 and
USP9X expression in OVCAR8 cells transfected with control siRNA (siNT) or siRNA targeting USP9X.
Cells were cultured in adherent conditions (Adh) or as spheroids (Sph). Densitometric analysis of
NUAK1 relative to tubulin and normalized to siNT-transfected controls. Two-way ANOVA and Tukey’s
multiple comparisons test was performed (** p < 0.01; *** p < 0.001; n = 3). Whole blot images can be
found in Figures S25–S27. (F) Immunoblot analysis of NUAK1 and LC3-I/II expression in OVCAR8 cells
treated with 25 µM chloroquine for 8 h or left untreated. Cells were cultured in adherent conditions
(Adh) or as spheroids (Sph). Densitometric analysis of NUAK1 relative to tubulin and normalized to
untreated controls. Two-way ANOVA and Tukey’s multiple comparisons test was performed (* p < 0.05;
n = 3). Whole blot images can be found in Figures S28–S31.

Time course analysis was completed in OVCAR8 spheroids to study these changes in NUAK1
expression in greater detail. During early spheroid formation, NUAK1 expression is relatively high
and this parallels phospho-LKB1 Ser428 levels in spheroids (Figure 2B). The NUAK1 levels decrease
significantly when compared to adherent cells later during spheroid formation and again this correlates
with reduced phospho-LKB1 with a statistically significant decrease observed by 72 h. NUAK1
maintains a low yet detectable level at these later points.
To investigate this increase in NUAK1 in EOC spheroids, we first performed RT-qPCR to determine
whether NUAK1 is down-regulated at the transcript level. There was no significant difference in
NUAK1 gene expression between adherent cells and spheroids (Figure 2C). Furthermore, there was no
significant difference in NUAK1 mRNA between OVCAR8 and OVCAR8-STK11KO cells and spheroids.
These results suggest that down-regulated NUAK1 expression is controlled at the protein level.
Previous studies have shown that the ubiquitin-proteasome system (UPS) can regulate NUAK1 [29].
We treated cells and spheroids with the proteasome inhibitor, MG132, to test whether the UPS controls
NUAK1 expression in EOC. The addition of MG132 to OVCAR8 cells not only prevented the NUAK1
decrease observed in spheroids, but it significantly increased its levels (Figure 2D). This effect of
proteasome inhibition on NUAK1 was observed in both adherent cells (MG132-treated:DMSO-treated
ratio of 1.98) and spheroids (ratio of 1.75). Intriguingly, MG132 did not increase NUAK1 expression in
OVCAR8 spheroids lacking LKB1 (Figure 2D), in which we observed a ratio of 0.74 as compared with
1.51 for OVCAR8-STK11KO adherent cells. These results support the importance of LKB1 in regulating
NUAK1 expression levels in spheroids, and that the UPS contributes to its down-regulation.
A previous report demonstrated that the activity of Ubiquitin Specific Peptidase 9 X-Linked
(USP9X) removed NUAK1 ubiquitination [30]. Further to our result of the UPS controlling NUAK1
expression in EOC, we tested whether USP9X can regulate NUAK1 in spheroids. We predicted that
USP9X knockdown would lead to decreased NUAK1 via proteasomal degradation. Indeed, USP9X
knockdown significantly decreased NUAK1 in OVCAR8 adherent cells and spheroids (Figure 2E).
Spheroids were treated with the lysosomotropic autophagy inhibitor, Chloroquine (CQ),
to determine whether lysosomal degradation also contributes to decreased NUAK1. CQ treatment led
to a significant increase in NUAK1 in OVCAR8 spheroids, where there was a CQ-to-control ratio of
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2.63 as compared with a ratio of only 1.20 for adherent cells (Figure 2F). We observed the buildup in
LC3-I and -II proteins, as expected for late-stage autophagy inhibition with this agent [31]. Altogether,
these findings suggest that protein stability in EOC cells and spheroids primarily controls NUAK1
protein levels.
2.3. NUAK1 Promotes EOC Cell Adhesion and Spheroid Integrity
Prior studies have shown that NUAK1 plays a role in cell adhesion. NUAK1 promotes
epithelial-to-mesenchymal transition (EMT) in cancer and induces cell detachment by regulating the
MYPT-PP1β complex [22,24,32]. Cell adhesion is critical during EOC metastasis, because cell-ECM
interactions mediate the spheroid formation and subsequent re-attachment at secondary sites [10].
We used OVCAR8, OVCAR3, and HEYA8 to further investigate this function of NUAK1 in EOC
metastasis, because they readily form spheroids in vitro and can establish xenografted tumours
when injected intraperitoneally into immune-compromised mice [28,33]. OVCAR8 cells express
high levels of NUAK1, while OVCAR3 and HEYA8 cells express very low to undetectable NUAK1
protein (Figure 3A). We generated three independent stable clonal lines lacking intact NUAK1
expression (OVCAR8−NUAK1KO) while using CRISPR-Cas9 genome editing; and in a reciprocal
fashion, we engineered multiple clones of OVCAR3 and HEYA8 cell lines to stably overexpress NUAK1
(OVCAR3 + NUAK1 and HEYA8 + NUAK1; Figure 3A). We performed timed adhesion assays to
examine whether NUAK1 controls cell attachment. HEYA8+NUAK1 cells had significantly greater
single cell adhesion when compared to HEYA8 empty-vector control cells; likewise, this was observed
in OVCAR3+NUAK1 cells (Figure 3B). In contrast, OVCAR8−NUAK1KO cells had significantly lower
cell adhesion when compared to parental OVCAR8 cells. Thus, our results support previous studies
that NUAK1 enhances EOC cell adhesion.
Given this result, we next investigated whether NUAK1 is required for proper EOC spheroid
formation. The cells were cultured in Ultra-Low Attachment (ULA) culture plates and methylcellulose
was added to the media to facilitate spheroid formation [34]. After extensive growth in suspension
culture, OVCAR8 cells formed dense spheroids as expected (Figure 3C). However, OVCAR8-NUAK1KO
spheroids were markedly less compact and exhibited a disaggregated appearance. To further examine
this altered phenotype and visualize cell viability, OVCAR8 and OVCAR8-NUAK1KO cells were stably
transduced with NucLight GFP lentivirus. Phase contrast and green fluorescence images were captured
during single spheroid culture using an IncuCyte Zoom. Using the same time point as in Figure 3C,
we observed intact spheroids with robust green fluorescence signal for OVCAR8-GFP cells (Figure 3D).
In contrast, OVCAR8-NUAK1KO-GFP spheroids showed decreased integrity with many extruding
non-viable cells, as visualized by the loss of green fluorescence signal. Taken together, NUAK1 loss
reduces EOC cell adhesion, leading to decreased spheroid integrity.
2.4. NUAK1 Promotes EOC Spheroid Formation through Fibronectin Expression
We opted to perform global transcriptome analysis to understand the molecular basis for the
impaired spheroid integrity in OVCAR8-NUAK1KO spheroids. A total of 606 genes were differentially
expressed (fold change ≥ 2 or ≤ −2) at 24 h between OVCAR8 and OVCAR8-NUAK1KO spheroids while
using the Affymetrix Human Clariom S microarray (Table S4). Hierarchical clustering demonstrated
that there were distinct gene expression profiles between OVCAR8 and OVCAR8-NUAK1KO spheroids
(Figure 4A). Gene Set Enrichment analysis (GSEA) using this transcriptome data was completed to
determine potential mechanisms controlled by NUAK1. Using the Hallmark and Curated Canonical
databases in GSEA, it was revealed that the interferon, metabolism, and EMT signatures were enriched
in OVCAR8 spheroids when compared with OVCAR8-NUAK1KO (Figure 4B; Tables S5 and S6),
which supports a previous study showing NUAK1 can promote EMT in EOC cells [23]. Interestingly,
we found multiple pathways involving integrin-mediated cell attachment that were decreased due to
NUAK1 loss in spheroids (Figure 4C; Table S7), thus supporting our in vitro cell adhesion results.
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shown. (B) Top 10 gene sets up-regulated in OVCAR8 spheroids when compared with OVCAR8-NUAK1KO
spheroids presented as normalized enrichment score (NES) using the GSEA Hallmark and Curated
Canonical databases. (C) Reactome integrin cell surface interactions enrichment plot with normalized
enrichment score (NES), nominal p-value, and FDR q-value are shown. (D) RT-qPCR validation of
genes selected from the integrin cell surface interactions signature. Fold-change in mRNA levels
is presented for OVCAR8 and OVCAR8-NUAK1KO spheroids. Statistical analysis was performed
using two-tailed Student’s t-test (*** p < 0.001; **** p < 0.0001; n = 3). (E) Immunoblot analysis
of fibronectin and L1CAM in OVCAR8 − NUAK1KO and HEYA8 + NUAK1 cells with respective
parental cell lines cultured in adherent conditions (ADH) or in suspension (SPH). Tubulin was
used as a loading control. Densitometric analysis of fibronectin and L1CAM relative to tubulin,
normalized to adherent cells. Two-way ANOVA and Tukey’s multiple comparisons test was performed
(* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; n = 3). Whole blot images can be found in
Figures S38–S45. (F) Immunofluorescence analysis of fibronectin (green) in OVCAR8 − NUAK1KO
and HEYA8 + NUAK1 spheroids with respective parental cell lines. Phalloidin (red) and DAPI
(blue) were used as actin cytoskeleton and nuclear stains, respectively. Images were captured using
Olympus AX70 upright microscope and ImagePro image capture software; representative images from
three independent experiments are shown. Scale bar represents 100 µm. (G) Images of OVCAR8
and OVCAR8-NUAK1KO spheroids cultured for 11 days in ULA dishes with methylcellulose and
supplemented with or without 5 µg/mL plasma fibronectin (pFN) captured using a Leica inverted
light microscope. Representative images from three independent experiments are shown. Scale bars
represent 100 µm. Circularity index was measured and calculated using Fiji as described in Materials
& Methods. One-way ANOVA and Tukey’s multiple comparisons test was performed (* p < 0.05;
** p < 0.01; n = 3).

Individual genes with a greater than two-fold change from this dataset were chosen to validate
by RT-qPCR. While L1CAM was not a core enriched gene within the Reactome Integrin Cell Surface
Interaction dataset, it was included, since this transmembrane adhesion molecule promotes EOC
spheroid formation in concert with fibronectin [35]. Furthermore, it was the 10th most down-regulated
gene in OVCAR8−NUAK1KO spheroids out of all differentially expressed genes (Table S4). We observed
a significant decrease in FN1 mRNA levels in OVCAR8-NUAK1KO spheroids, and a coordinate
reduction in L1CAM mRNA (Figure 4D). Interestingly, while there was no change in expression level
of the canonical fibronectin receptor genes, ITGA5 and ITGB1, there was a significant decrease in other
integrins, namely ITGB5 and ITGB8, as well as the adhesion molecules thrombospondin 1 (THBS1) and
F11 receptor (F11R).
We first assessed fibronectin and L1CAM to further investigate this altered expression of cell
adhesion molecules at the protein level. In comparison to adherent cells, OVCAR8 spheroids had
increased fibronectin expression with multiple isoforms being detected (Figure 4E). Multiple fibronectin
isoforms have been attributed to an up-regulation of proteinase activity [36,37], including matrix
metalloproteinase-2 (MMP-2), which is up-regulated and cleaves fibronectin to enhance binding to
its integrin receptors [14]. Strikingly, there was no detectable fibronectin in OVCAR8-NUAK1KO
spheroids. In contrast, HEYA8 + NUAK1 cells and spheroids displayed a dramatic increase in
fibronectin expression compared to HEYA8 empty-vector control cells and spheroids (Figure 4E).
Similar to fibronectin, L1CAM expression was decreased in OVCAR8−NUAK1KO in comparison with
OVCAR8 adherent cells and spheroids, yet was markedly increased in HEYA8 + NUAK1 spheroids
relative to HEYA8 (Figure 4E). These results were further supported by immunofluorescence analysis
showing striking fibronectin loss in OVCAR8−NUAK1KO spheroids, but dramatically increased
expression in HEYA8 + NUAK1 spheroids (Figure 4F). Therefore, our results strongly suggest that
NUAK1 regulates fibronectin expression in EOC spheroids.
We treated spheroids with exogenous plasma fibronectin (pFN) to determine whether NUAK1
regulation of fibronectin impacts spheroid integrity. Upon the initiation of spheroid culture, pFN at
5 µg/mL was supplemented to OVCAR8 and OVCAR8-NUAK1KO cells. After the same time period as in
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Figure 3C,D, OVCAR8−NUAK1KO spheroids appeared densely packed without protruding peripheral
cells, as seen in untreated NUAK1KO counterparts (Figure 4G). Indeed, we found that exogenous
fibronectin treatment of OVCAR8−NUAK1KO spheroids significantly increased the circularity index
as compared with untreated OVCAR8−NUAK1KO spheroids (Figure 4G). In contrast, we observed no
difference in the ability of individual OVCAR8−NUAK1KO cells to attach to fibronectin-coated plates
as compared with OVCAR8 parental cells (data not shown) [38]. Thus, NUAK1 is required to promote
spheroid integrity, likely through its regulation of fibronectin expression and resultant deposition.
2.5. NUAK1 Loss in OVCAR8 Cells Extends Survival of Xenografted Mice
The findings from our in vitro data suggest that NUAK1 increases EOC cell adhesion and enhances
spheroid integrity. Since spheroids have a critical role in EOC metastasis, we investigated the effect
of NUAK1 loss in a xenograft mouse model of intraperitoneal metastasis. We found that survival
was significantly increased in host female mice that were injected i.p. with OVCAR8−NUAK1KO
cells as compared with OVCAR8 cells (Figure 5A), with a median survival increase of 20.8%
(plog-rank
= 12,
0.0178).
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x
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We assessed fibronectin directly in tumour xenografts since our in vitro results indicated that
NUAK1 promotes spheroid formation through fibronectin expression and deposition. We observed
decreased fibronectin immunostaining in OVCAR8−NUAK1KO tumours when compared to OVCAR8
controls (Figure 5B). Lastly, we assessed the association between NUAK1 and fibronectin expression
in patient tumours. Using The Cancer Genome Atlas (TCGA) ovarian serous cystadenocarcinoma
dataset, we found a significant positive correlation (Pearson correlation: 0.63, p = 5.10 × 10−35 ) between
NUAK1 and FN1 mRNA expression in tumours from EOC patients (Figure 5C). Overall, our results
indicate that NUAK1 is required for efficient EOC metastasis, likely via its regulation of fibronectin
expression during the spread of disease.
3. Discussion
Advanced-stage EOC is commonly characterized by malignant ascites containing spheroids,
which are a key mediator of intraperitoneal metastasis and facilitate chemoresistance [4,9]. Our group
previously reported that the master kinase LKB1 is required for efficient EOC metastasis [15,16].
We completed a multiplex inhibitor bead-mass spectrometry analysis and identified NUAK1 as a
top candidate substrate to elucidate the downstream target eliciting the pro-metastatic function of
LKB1. NUAK1 is differentially expressed in quiescent spheroids when compared to proliferative
monolayer cells and this is regulated by lysosome degradation and the UPS. NUAK1 increases EOC
cell adhesion and promotes spheroid integrity via fibronectin expression and subsequent deposition,
and this coordinate expression is also seen in human serous tumours. Finally, NUAK1 loss in EOC
cells extends xenograft host survival, and the resultant tumours also lack fibronectin. Altogether,
we propose that the LKB1 target NUAK1 has metastasis-promoting functions by facilitating spheroid
integrity through its regulation of fibronectin production.
LKB1 is known as a master kinase, since it acts through AMPK and twelve additional related
kinases called the ARKs to affect cell polarity, metabolism, and growth [17,19]. While LKB1 is commonly
regarded as a tumour suppressor, there is growing evidence implicating it as also having pro-metastatic
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functions [17,39]. We have previously demonstrated that LKB1 is required for EOC spheroid viability
in vitro and metastasis in vivo [15,16], and herein we observed that the total LKB1 protein expression
increases during late spheroid formation supporting its role in EOC metastasis. Since LKB1 serves a
broad range of necessary functions, it is critical to elucidate which of its downstream targets may be
more precise therapeutic targets. The most common substrate of LKB1 is AMPK; however, we have
evidence that LKB1 elicits its pro-metastatic actions in an AMPK-independent manner in EOC [15].
We identified NUAK1 as the most likely LKB1 target to further investigate in our in vitro metastasis
model system while using an unbiased mass spectrometry approach to survey active kinases. Indeed,
we demonstrate that LKB1 controls NUAK1 expression and phosphorylation, ultimately affecting
NUAK1 stability in EOC cells and spheroids. Previous studies have shown that the UPS plays a role
in regulating NUAK1 expression and stability. NUAK1 can be phosphorylated by cyclin-dependent
kinases and polo-like kinases, which leads to SCF E3 ligase-mediated NUAK1 polyubiquitination
and subsequent degradation [29]. NUAK1 is ubiquitinated by unique Lys29 and Lys33 linkages,
which block phosphorylation and activation by LKB1 [30]. However, USP9X binds to NUAK1 to cleave
the polyubiquitin modifications, thereby facilitating LKB1-mediated phosphorylation. In our report,
we show that USP9X is required for maintaining NUAK1 expression in EOC. While the UPS is the
primary degradation pathway for short-lived and small proteins, the autophagy-lysosome pathway
is another degradation system in eukaryotic cells that is responsible for the clearance of damaged
proteins, as well as a stress response during nutrient deprivation and hypoxia [40]. Indeed, our group
and others have shown that autophagy is activated in EOC, in which spheroids activate autophagy
as compared with adherent cells [41–44]. Our results while using the broad-acting lysosomotropic
agent chloroquine to block the late-stages of autophagy indicate that NUAK1 might be degraded by
autophagy-lysosome mechanisms, perhaps in a more general way during late spheroid formation.
Taken together, NUAK1 is an LKB1 target in EOC to control its differential expression and stability
between proliferative adherent cells and quiescent spheroids.
Multiple studies have provided evidence that NUAK1 can have tumour-promoting functions.
In human hepatoma cells, NUAK1 blocks programmed cell death by inhibiting caspase 8 [45].
In addition, NUAK1 can induce S-phase to promote cell proliferation [29]. Cancer cell survival is also
promoted by NUAK1 through altered metabolic homeostasis [46]. In MYC-overexpressing tumours,
NUAK1 reduces metabolic stress by inhibiting mTORC1 and sustaining glutamine metabolism.
Relevant to our own findings, an elevated NUAK1 expression correlates with poor prognosis in serous
EOC patients [24]. The molecular basis underlying this association with poor prognosis in EOC had not
previously been elucidated; however, we show that NUAK1 ablation in EOC cells extends xenografted
host survival. Moreover, NUAK1 promotes EOC cell adhesion and spheroid formation, which are
essential mediators of intraperitoneal metastasis.
During EOC metastasis, cell adhesion is critical, as cancer cells aggregate through cell–cell and
cell–ECM interactions to form spheroids and adhere to new sites [9]. NUAK1 has been documented to
play a role in cell adhesion through EMT and invasion. For example, NUAK1 increases EMT and cell
migration by inhibiting miR-1181 expression in EOC cells [23]. NUAK1 overexpression in a pancreatic
cancer mouse model increased metastasis [47]. NUAK1 can promote cell detachment by regulating
the myosin phosphatase complex in HEK293 and MEF cells [22]. Moreover, NUAK1 loss reduces
tumour-initiating capacity in colon cancer spheroids [21]. However, in our study we show that NUAK1
loss impairs EOC single cell adhesion to tissue-culture substratum as well as in spheroid formation.
We propose that NUAK1 controls the expression of important adhesion molecules and ECM substrates
required for the initial steps of spheroid formation. This would explain why NUAK1 protein and
phosphorylated-LKB1 are higher at early steps of spheroid formation yet decrease over time. Indeed,
the top gene expression signatures altered at 24 h in OVCAR8-NUAK1KO spheroids were related to cell
attachment. Interestingly, a previous study also observed several cell adhesion pathways affected by
NUAK1 using gene ontology analysis yet were not mechanistically pursued [21]. Herein, FN1 was the
most differentially expressed gene in spheroids due to NUAK1 loss. Importantly, we were able to rescue
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the defect in spheroid integrity due to NUAK1 loss by the addition of soluble fibronectin. Additionally,
we showed that xenografted tumours lacking NUAK1 had decreased fibronectin expression, and this
was complemented by a strong positive correlation between NUAK1 and FN1 in serous EOC tumours
from patients. Altogether, we have elucidated a novel mechanism of NUAK1 in promoting EOC cell
adhesion and spheroid compaction through fibronectin expression and matrix production.
Beyond just fibronectin, our transcriptome analysis indicated additional genes within a cell
attachment signature potentially affected by NUAK1, which included L1CAM, ITGβ8, ITGβ5, THBS1,
and F11R. This suggests that NUAK1 might regulate a network of adhesion molecules within EOC
spheroids. A previous study using OVCAR5 cells showed that fibronectin mediates spheroid formation
through its canonical α5β1 integrins [11]. Interestingly, these specific integrins were not altered in our
system, but rather the ITGβ5 and ITGβ8 were significantly reduced due to NUAK1 loss. One study
has shown that β8-integrin might interact with fibronectin; however, this was only observed in chick
sensory neurons and the alpha integrin was not identified [48]. Interestingly, a common ligand for both
β5- and β8-integrins is latency-associated peptide-transforming growth factor beta (LAP-TGFβ) [49],
and we have shown that active TGFβ signalling in EOC spheroids is critical for promoting EMT in
these structures [50]. Thus, NUAK1 might cross-talk to impact TGF β-mediated EMT in EOC spheroids,
as observed in other cancer cell systems [51]; this will be a focus of on-going study by our group.
Another study similarly demonstrated the importance of fibronectin in spheroids generated from
fallopian tube secretory epithelial (FTE) cells, which represent the cell-of-origin for high-grade serous
EOC [52,53]. FTE cells with TP53 mutations have an increased propensity to aggregate into spheroids
due to autocrine fibronectin deposition [54]. Others have observed that L1CAM acts to up-regulate
fibronectin expression in order to facilitate spheroid formation [35]. In our study, we similarly show a
strong coordinate regulation between L1CAM and fibronectin, implying that NUAK1 might be an
important upstream signal controlling their expression together to promote spheroid formation and
ultimately EOC metastatic potential.
4. Materials and Methods
4.1. Antibodies and Reagents
Antibodies against NUAK1 (#4458S), LKB1 (#3050S), p-LKB1-Ser428 (#3482S), LC3B (#2775),
and c-myc (#5605) were obtained from Cell Signaling Technology (Danvers, MA, USA).
Anti-tubulin antibody (#T5168), Anti-actin antibody (#A2066), anti-rabbit FITC secondary
antibody (# F9887), HRP-conjugated antibodies against mouse IgG (NA931V), and rabbit IgG
(NA934V), and 40 ,6-diamidino-2-phenylindole were purchased from Sigma (St. Lewis, MO, USA).
Chloroquine (#C-6628), MG132 (#M8699), and methylcellulose (#M0512) were also obtained from Sigma.
Anti-fibronectin (#ab2413) was purchased from Abcam (Cambridge, MA, USA). Antibody against
L1CAM (#SIG-3911) was obtained from Biolegend (San Diego, CA, USA). Anti-USP9X (A301-350A)
was purchased from Bethyl Laboratories (Montgomery, TX, USA). Alexa Fluor phalloidin and plasma
human fibronectin (#PHE0023) was obtained from Thermo Fisher Scientific (Waltham, MA, USA).
WZ4003 (#5177) was purchased from Tocris Bioscience.
4.2. Cell Culture and Treatments
OVCAR8 (ATCC, Manassas, VA, USA) and HEYA8 (ATCC) cells were cultured in RPMI-1640
(Wisent, St. Bruno, QC, Canada). The OVCAR5 cells (ATCC) were cultured in DMEM/F12
(Life Technologies, Carlsbad, CA, USA). Although one report suggests OVCAR5 cells may be of
gastrointestinal origin [55], this cell line was isolated from the ascites of an EOC patient and it maintains
the ability to form i.p xenografts with HGSOC histology [28]; therefore, we have included it our
study. Early passage ascites-derived cell lines (iOvCa147, iOvCa198, iOvCa247) were generated based
on a protocol that was previously described by us and cultured in DMEM/F12 [56]. Generation of
OVCAR8-STK11KO cells was described previously [15], and cultured the same as OVCAR8 cells.
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The growth media was supplemented with 10% fetal bovine serum (Wisent) for all cell lines. The cells
were grown in a humidified incubator at 37 ◦ C with 5% CO2 .
Adherent cells were maintained on tissue cultured-treated polystyrene (Sarstedt, Newton, NC,
USA). Spheroids were formed by maintaining cells on Ultra-Low Attachment (ULA) cluster plates
(Corning, NY, USA), which have a hydrophilic and neutral coating to prevent cell attachment,
as described previously [7,16,41]. For specific experiments, day-3 adherent cells and spheroids were
treated with 0.1% DMSO or MG132 (10 µM) for 8 h; cells were treated with chloroquine (25 µM) for 8 h
or left untreated.
4.3. Generation of OVCAR8-NUAK1KO Cells
Two independent 20-nucleotide guide sequences targeting the NUAK1 gene 50 -GTGGC GGGGG
ACCGC CCCGA-30 (site 1) and GGGTC TCCTG CAGCT CGTAG CGG-30 (site 2) were selected while
using CRISPR Design Tool (http://tools.genome-engineering.org). Complementary oligonucleotides
50 -CACCG TCGGG GCGGT CCCCC GCCAC-30 and 50 -CACCG GGGTC TCCTG CAGCT CGTAG-30
for site 1 and 50 -CACCG GGGTC TCCTG CAGCT CGTAG-30 and 50 -AAACC TACGA GCTGC AGGAG
ACCCC-30 for site 2 (Sigma-Genosys) were annealed and ligated into the BbsI-digested restriction
endonuclease site of pSpCas9(BB)-2A-Puro plasmid [57] (gift from Dr. F. Dick, Western University) to
generate the pSpCas9-sgNUAK1-1 and -2 plasmids. Cells were seeded at 200,000 cells/well into 6-well
plates and transfected with 0.5 µg each of pSpCas9-sgNUAK1 plasmids while using LipofectAMINE
2000 (Invitrogen) according to the manufacturer’s instructions. Media containing 1 µg/mL puromycin
was replaced the following day, and cells were treated for one day. After growth recovery, the cells
were trypsinized, counted, and seeded into 96-well plates to perform limiting dilution subcloning of
NUAK1-knockout cells. Single colonies were expanded for protein isolation and the confirmation of
NUAK1 loss by western blotting. Three clones lacking NUAK1 protein expression were identified
and verified by genomic DNA isolation and Sanger sequencing (London Regional Genomics Centre,
Robarts Research Institute).
4.4. Generation of HEYA8 and OVCAR3 NUAK1 Overexpressing Cells
HeyA8 and OVCAR3 cells were transfected with pPHAGE C-TAP-NUAK1 (HsCD00462473;
Harvard PlasmID Database) while using Lipofectamine 2000 (Invitrogen) according to manufacturer’s
instructions. Forty-eight hours post-transfection, 1 µg/mL puromycin (Sigma) treatment was started,
and then cells were re-plated into 10-cm dishes and selection was continued until colony formation.
Colonies were picked and expanded prior to screening for NUAK1 expression by western blot using
lysates from parental cell lines for comparison. Empty vector control (EVC) cells were generated while
using the pPHAGE C-TAP plasmid for both cell lines and represent four pooled clones of each line
subjected to the same puromycin selection process.
4.5. Spheroid Live-Cell Microscopy
The cells were seeded in a 24-well ULA dish at 1000 cells per well and cultured in complete
media and methylcellulose [34]. For the fibronectin rescue experiment, 5 µg/mL plasma fibronectin
was included in the media. After 11 days, spheroids were washed with PBS and transferred to a
new ULA dish with only complete media. The images were immediately taken with the Leica DMI
4000B inverted microscope using the Leica Application Suite version 4.4 software. The circularity of
spheroids was analysed through Fiji Is Just ImageJ (Fiji) (http://fiji.sc), and 7–10 individual spheroids
were analysed per experiment. A pixel size range of 1000–infinity and a circularity range of 0–1.0 was
used for all images.
OVCAR8 and OVCAR8-NUAK1KO cells stably-transduced with lentivirus expressing
NucLightGFP (Sartorius) were seeded at 5000 cells per well in 96-well round-bottom ULA cluster
plates (Corning). The spheroids were imaged using the IncuCyte Zoom (Sartorius) every 3 h for up to
17 days.
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4.6. Cell Adhesion Assay
The cells were seeded in a 24-well adherent dish at 200,000 cells per well. At specific time points
for each EOC cell line (15 min for HEYA8 cells, 2 h for OVCAR3 cells, and 4 h for OVCAR8 cells),
non-adherent cells were aspirated, the plate was washed with PBS, and adherent cells were counted by
Trypan Blue Exclusion cell counting in order to quantify single viable cell adhesion.
4.7. Immunofluorescence
The spheroids were embedded in cryo-matrix (Thermo Fisher) and sectioned at 5 µm with
Shandon cryostat microtome. Cryosections were fixed (10% formalin solution), permeabilized (0.1%
Triton X-100 in PBS), and then blocked (5% BSA in 0.1% Triton X-100). After overnight incubation with
anti-fibronectin antibody (1:100; #ab2413), sections were washed with PBS and then incubated for 1 h
with anti-rabbit FITC secondary antibody (1:300; # F9887). For counterstaining, sections were
incubated for 1 h with Alexa Fluor phalloidin (1:1000), followed by incubation for 1 h with
40 ,6-diamidino-2-phenylindole (1:1000). Sections were mounted on coverslips with Vectashield
(Vector Laboratories, Burlingame, CA, USA). Fluorescence images were captured while using Olympus
AX70 upright microscope and ImagePro image capture software.
4.8. Multiplexed Inhibitor Bead Chromatography
Lysates were collected from OVCAR8 parental and OVCAR8-STK11KO cells that were cultured
as adherent cells and spheroids. Multiplexed Inhibitor Bead (MIB) Chromatography was performed,
as described below.
Broad spectrum Type I kinase inhibitors (CTx0294885, VI-16832, PP58, Purvalanol B, UNC-2147A,
UNC-8088A) were custom-synthesized with hydrocarbon linkers and terminal amine groups and
covalently attached to ECH-activated Sepharose beads, as previously described [58], to form the
multiplexed inhibitor beads (gift from Gary Johnson, UNC). The enrichment of kinases from OVCAR8
cells by MIB chromatography was adapted from [25]. The cell pellets were lysed in MIB lysis buffer
(50 mM HEPES pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, 1 mM EGTA freshly supplemented
with 10 mM NaF, 2.5 mM NaVO4 , protease inhibitor cocktail (Sigma–Aldrich, Catalog #P8340),
phosphatase inhibitor cocktail 2 (Sigma–Aldrich, Catalog #P5726), and phosphatase inhibitor cocktail
3 (Sigma–Aldrich, Catalog #P0044)) while on ice for 20 min. The lysate was homogenized with an
18-gauge syringe needle and centrifuged at 20,800× g for 15 min at 4 ◦ C. The total protein amount in
the supernatant was quantified using the Bio-Rad protein assay (Catalog #5000006) according to the
manufacturer’s instructions. The supernatant was brought to 1 M·NaCl and 4 mg of total protein was
loaded on a column (Bio-Rad, Catalog #731–1550) of 100 µL packed ECH sepharose 4B (GE Healthcare,
Catalog # 17057101), pre-equilibrated with 2 mL of high salt Buffer B (50 mM HEPES pH 7.5, 1 M·NaCl,
0.5% Triton X-100, 1 mM·EDTA, 1 mM·EGTA). The flowthrough was transferred to a column consisting
of layered MIBs (50 µL each of a 50% slurry of CTx0294885, VI-16832, PP58, Purvalanol B, UNC-2147A,
and UNC-8088A) pre-equilibrated with 2 mL of Buffer B. The flowthrough was reapplied to the column
and the column was then washed with 5 mL of Buffer B and 5 mL of 50 mM ammonium bicarbonate
(ABC). After washing, the beads were transferred to 1.5 mL centrifuge tubes in 1 mL of 50 mM ABC and
then washed twice more in 1 mL of 50 mM ABC. The samples were digested overnight at 37 ◦ C with
1 µg trypsin and LysC (Promega, Catalog # V5073). The supernatant was collected and the samples
were reduced in 5 mM DTT at 53 ◦ C for 30 min., cooled to room temperature, and then alkylated in
10 mM iodoacetamide in the dark at RT for 45 min. Trypsin (Sigma–Aldrich, Catalog # T6567) was
added and the samples were incubated at 37 ◦ C for 4 h. Formic Acid was added to a final concentration
of 2%, and the samples were dried by speed vac.
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4.9. Mass Spectrometry Analysis
The digested peptides were dissolved in 5% Formic Acid and then transferred to autosampler
vials for analysis by nano-LC-MS/MS while using a SCIEX 5600 TripleTOF mass spectrometer and
an Eksigent Ultra nanoHPLC. The samples were loaded onto a home-packed emitter tip column
(15 cm × 75 um; 3 µm·C18, Reprosil, Dr. Maisch). After sample loading, a linear gradient from 2%
acetonitrile to 35% acetonitrile over 90 min. at 200 nL/min was used to elute all peptides. A further
increase to 80% acetonitrile from 90–95 min., hold from 95–105 min. at 80% acetonitrile, and return to
2% acetonitrile from 105 min. to 120 min. was used to ensure full peptide elution. During peptide
elution, data were acquired on the mass spectrometer in data-independent acquisition (DIA) mode.
Cycle time was 3.5 s, consisting of a 250 ms MS1 scan (400–1250 Da) and 34 × 25 Da SWATH windows
covering the range of 400–1250 m/z.
4.10. Mass Spectrometry Data Analysis
All of the raw MS files were saved in our local interaction proteomics LIMS, ProHits [59].
The WIFF raw files were converted into mzXML format while using the SCIEX converter through
the Proteowizard module implemented within ProHits. The mzXML files were processed by the
signal extraction (SE) module of DIA-Umpire [60] (version 2.0) to generate pseudo MS/MS spectra
for data base searches. The following parameters were used: isolation window (fixed, 25 Da),
fragment grouping (RPmax 25, RFmax 300, correlation threshold 0.2, delta apex 0.6, RT overlap 0.3),
signal extraction parameters [mass tolerance (30 ppm MS1, 40 ppm MS2), signal to noise (2 for MS1
and MS2), minimum intensity threshold (1 for MS1, 0.1 for MS2), charge state range (2+ to 4+ for MS1
and MS2), maximum curve in RT range (1.5), and resolution (17,000)]. The files were searched using X!
tandem (version Jackhammer, 2013.06.15.1) and Comet (version 2014.02 revision 2) using the following
parameters: allow tryptic peptides only, carbamidomethylation on cysteine as a fixed modification,
and deamidation on asparagine and glutamine, oxidation on methionine, and phosphorylation on
serine, threonine and tyrosine as variable modifications. Additional Comet parameters were two
missed cleavages, monisotopic parent and fragment mass, 35 ppm peptide mass tolerance, 2+ to
4+ precursor charge state, fragment ion binding (1.005 amu with 0.4 offset). Additional X! tandem
parameters were: one missed cleavage, 50 ppm parent mass error, 40 ppm fragment mass error,
monoisotopic fragment, and 4+ maximum parent charge. The searched database contained the human
and adenovirus complements of the RefSeq protein database (version 57) supplemented with “common
contaminants” from the Max Planck Institute (http://141.61.102.106:8080/share.cgi?ssid=0f2gfuB) and
the Global Proteome Machine (GPM; http://www.thegpm.org/crap/index.html), as well as sequences
from common fusion proteins and epitope tags. The sequence database consisted of forward and
reversed sequences; in total, 72,226 sequences were searched. The resulting Comet and X! tandem
search results were individually processed by PeptideProphet [61], and the peptides were assembled
into proteins while using parsimony rules that were first described in ProteinProphet [62] into a
final iProphet [63] protein output using the Trans-Proteomic Pipeline (TPP; Linux version, v4.7,
Polar Vortex rev 1, Build 201410231114). The TPP options were as follows: general options were
-p0.05 -x20 -PPM - d”DECOY,” iProphet options were pPRIME and PeptideProphet options were
pPAEd. Parameters for DIA-Umpire Quant (version 2.0) were peptide FDR (0.05), protein FDR (0.05),
probability threshold (0.9), filter weight (group), minimum weight (0.9), top number of fragments (20),
top number peptides (20), and frequency (0). mapDIA analysis [64] (version 2.3.3) was then performed
on the DIA-Umpire results for intensity normalization, selection of fragments and peptides, and the
determination of significantly changed proteins. For this, only peptides that were unique at the gene
level were considered. mapDIA used the following parameters: impute (group 0.9, missing values are
assigned 0.9 of the smallest value of the group in the row; if none above zero, then 0.9 the smallest
value of the column), experimental design (replicate), normalization (retention time normalized with
standard deviation of 10, rounded to two decimal places (RT 10 2)), standard deviation factor (SDF)
filter (2), minimum correlation (2), minimum observation (2), minimum fragments per peptide (3),
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maximum fragments per peptide (5), minimum peptides per protein (2), maximum peptides per protein
(infinity), minimum proportion of differentially expressed proteins (0.01), and maximum proportion of
differentially expressed proteins (0.99). All of the MS data will be made available through the MassIVE
repository at ftp://massive.ucsd.edu/MSV000085252/.
4.11. Protein Isolation and Immunoblot Analysis
The cells were collected after washing the plate with PBS and scraping cells in lysis buffer [50 mM
HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl2 , 1 mM EGTA, 1 mM sodium orthovanadate,
10 mM sodium pyrophosphate, 10 mM NaF, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM
PMSF. 1X protease inhibitor cocktail (Roche, Laval, QC, Canada), and 225 mM β-glycerophosphate]
in order to obtain whole cell lysates from adherent culture. Spheroids were centrifuged at 2400 rpm
for 5 min., media was aspirated, and the pellet was washed in ice-cold PBS. After the removal of
PBS, lysis buffer was added to the pellet. Protein was isolated and the protein concentration in the
supernatant was measured by Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). The protein
was isolated from xenograft tumour samples collected from a previous study [15] by homogenizing
flash-frozen tissue in lysis buffer without β-glycerophosphate.
For immunoblot analysis, 30–50 µg of protein was resolved by SDS-PAGE using 6%, 8%, or 12%
gels. The proteins were transferred at 100 V for 1 h to a PVDF membrane (Roche), blocked with
5% milk or 5% BSA diluted in TBST (10 mM Tris–HCl, pH 8.0, 150 mM·NaCl and 0.1% Tween-20).
The membranes were incubated with primary antibodies overnight at 4 ◦ C. Membranes were incubated
for 1 h with peroxidase-conjugated anti-rabbit or anti-mouse antibodies (1:10,000 in 5% BSA/ TBST) and
exposed to chemiluminescence reagent to obtain whole cell lysates from adherent culture (Luminata
Forte, Millipore, Temecula, CA, USA). The images were captured using the ChemiDoc™ Imaging
System (Bio-Rad) and the bands were quantified using Image Lab 4.1 software.
4.12. PhostagTM Western Blot
PhostagTM lysis buffer was prepared similar to above; however, EGTA, sodium pyrophosphate,
and β-glycerophosphate were excluded from the preparation. PhostagTM gels were prepared while
using PhostagTM solution (Wako Chem, Richmond, VA, USA) and 10 mM MnCl2 , as 8% acrylamide
gels, according to manufacturer’s protocol. Electrophoresis was run for ~3 h, after which gels were
washed for 10 min. with 1× transfer buffer containing 1 mM EDTA, followed by 10 min. with 1×
transfer buffer without EDTA. Wet transfer was run for 1 h to PVDF membranes (Immobilon-P).
The membranes were incubated in primary antibody for two days, and imaging was performed as
described above.
4.13. Quantitative RT-PCR
Total RNA was isolated from adherent cells and spheroids while using the RNeasy Mini Kit
(Qiagen, Hilden, Germany). The concentration and purity of the RNA were determined with the
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Reverse transcription
was performed using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City,
CA, USA). The resulting cDNA was used for quantitative PCR while using Brilliant SYBR Green QPCR
Master Mix (Agilent Technologies/Stratagene, Mississauga, ON, Canada) and run on the Quantstudio
3 instrument (Applied Biosystems). Table S1 lists human-specific primer sequences (Sigma). GAPDH
was used as an internal control, and relative gene expression was quantified using the ∆∆Ct method.
4.14. Transcriptome Analysis and GSEA
The RNA was isolated from OVCAR8 and OVCAR8-NUAK1KO adherent cells and spheroids,
as described above. The RNA was reverse transcribed into cDNA and then labelled with biotin using
the Affymetrix Genechip WT pico kit (Thermo Fisher Scientific). The labelled cDNA was hybridized
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to the Human Clariom S microarray (Thermo Fisher Scientific). After washing, the microarray was
scanned while using the Affymetrix Gene Chip Scanner 3000. Data analysis was completed with
the Transcriptome Analysis Console software at The Centre for Applied Genomics (TCAG Facility,
SickKids Hospital).
Pathway analysis was completed using Gene Set Enrichment Analysis (GSEA) version 3.0 that was
developed by the Broad Institute at MIT [65]. The gene list was imported into GSEA without limiting
the genes by applying cut-offs. The Hallmark collection of 50 gene sets and the Curated Canonical
collection of 1329 gene sets from the Molecular Signatures Database (MSigDB, Broad Institute) were
used for the analysis. These gene sets were limited to those with 15 to 500 genes. Permutations were
completed 1000 times. Signal-to-noise was calculated and used to rank genes based on their differential
expression, where significance was set at p < 0.05 and FDR < 0.25.
4.15. TCGA Correlation Analysis
Correlation analysis of NUAK1 and FN1 mRNA expression (RNA Seq V2 RSEM) was performed
while using the Firehose Legacy dataset from The Cancer Genome Atlas (TCGA) Ovarian Serous
Cystadenocarcinoma in cBioPortal [66,67].
4.16. Xenotransplantation Assays
Female NOD/SCID mice (Charles River, 8–10 weeks old) were intraperitoneally injected with
4 × 106 OVCAR8 or OVCAR8-NUAK1KO cells in 150 µL of sterile PBS. The mice were monitored
every day and provided chow (cat. No.2919, Envigo) and water ad libitum. Euthanasia occurred
when humane endpoint criteria were met and necropsy was performed as described previously [15].
The Institutional Animal Care and Use Committee of the University of Western Ontario (AUP # 2017-065)
approved all of the animal experiments and carried out in accordance with the approved guidelines.
4.17. Statistical Analysis
Statistical analysis was completed using GraphPad PRISM 7 (GraphPad Software, San Diego, CA,
USA). Analyses were performed while using two-tailed Student’s t-test, multiple t-test with Bonferroni
correction, one-way ANOVA, followed by Dunnett’s post hoc test, or two-way ANOVA followed by
Tukey’s post-hoc test. A p-value less than 0.05 was considered to be statistically significant.
5. Conclusions
NUAK1 serves as a key LKB1 target in EOC to promote its pro-metastatic functions via cell
adhesion and spheroid integrity. We propose that NUAK1 controls fibronectin expression in spheroids,
leading to its deposition within the ECM, thereby facilitating EOC metastasis. Since LKB1 serves
multiple key functions that may make it unsuitable for targeted inhibition, then the identification
of NUAK1 as a key mediator acting immediately downstream could serve as a better drug target.
Indeed, there are several small molecule inhibitors directed against NUAK1/2 [68,69] and these could
be directly tested, or used as scaffolds for deriving more efficacious agents in the future. Altogether,
our latest results suggest that the LKB1 substrate NUAK1 might serve as a novel therapeutic target in
advanced-stage EOC.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/5/1250/s1,
Figures S1–S45 represent the whole blot images for Figure 1A,C,D,E, Figure 2A,B,D,E,F, Figures 3A and
4E. Table S1: Primer sequences for qPCR, Table S2: Differentially expressed kinases (FDR < 0.05 from
mapDIA) from MIB/MS analysis completed using OVCAR8 parental and OVCAR8 STK11-KO adherent cells,
Table S3: Differentially expressed kinases (FDR < 0.05 from mapDIA) from MIB/MS analysis completed using
OVCAR8 parental and OVCAR8 STK11-KO spheroids, Table S4: Differentially expressed genes from the
Affymetrix Clariom S array using OVCAR8 parental and OVCAR8 NUAK1-KO spheroids, Table S5: Signatures
from the GSEA Hallmark database that were enriched in the OVCAR8 parental spheroids compared to
NUAK1-KO spheroids, Table S6: Signatures from the Curated Canonical database that were enriched in
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the OVCAR8 parental spheroids compared to NUAK1-KO spheroids, Table S7: Core enriched gene set from
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTION signature.
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